Skip to main content
. 2023 Aug 26;95:104773. doi: 10.1016/j.ebiom.2023.104773

Fig. 1.

Fig. 1

Survival curves for each CD4/CD8 cut-off. Survival probability and odds ratio (95% CI) for each subgroup of participants. The outcome studied is the cumulative incidence of serious non-AIDS events. The baseline visit (month 0 of follow-up) corresponds to 24 months after antiretroviral therapy initiation. The OR of presenting a clinical event corresponds to the five-year follow-up period.